Inclusion Criteria:

• Patients with microscopic stage II or IIIA resectable gastric cancer
• Patients who have not received preoperative cancer therapy (radiotherapy, chemotherapy or immunotherapy)
• Patients with serum immunosuppressive acidic protein (IAP) measured within 2 weeks before surgery
• Patients with no metachronous or synchronous multiple cancer
• Patients without severe impairment of renal, hepatic and bone marrow functions
• Patients who are judged to be capable of tolerating surgery
• Patients with preoperative performance status 0 to 2
• Patients with no serious concurrent complications (such as bone marrow suppression, diarrhea and infection)
• Patients who are judged to be capable of tolerating this treatment, and who have given written informed consent to participate in this study

Exclusion Criteria:

• Patients with fresh hemorrhage from the gastrointestinal tract
• Patients with retention of body fluid necessitating treatment
• Patients with infection, intestinal palsy or intestinal occlusion
• Patients who are pregnant or hope to become pregnant during the study period
• Patients with diabetes treated by continuous use of insulin or showing poor glycemic control
• Patients with a history of ischemic heart disease
• Patients with concurrent psychiatric disease or psychotic symptoms, and judged to have difficulties participating in the study
• Patients receiving continuous administration of steroids
• Patients who have experienced serious drug allergy in the past
• Others, patients judged by the investigator or subinvestigator to be inappropriate as subject